Nanotechnology Stocks To Keep An Eye On - April 18th

OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, and Virpax Pharmaceuticals are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares in companies that focus on research, development, and the production of materials and devices at the nanoscale. These companies apply principles of nanoscience to innovate across a range of sectors, including electronics, healthcare, and energy, offering potential high-growth opportunities alongside the risks typical of emerging technologies. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.OSI Systems (OSIS)OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.Shares of NASDAQ:OSIS traded up $4.84 during trading on Friday, reaching $194.19. 249,990 shares of the stock were exchanged, compared to its average volume of 184,277. The firm has a market cap of $3.26 billion, a PE ratio of 24.99, a PEG ratio of 1.81 and a beta of 1.19. The stock has a 50-day moving average price of $194.56 and a 200-day moving average price of $175.37. The company has a current ratio of 1.88, a quick ratio of 1.25 and a debt-to-equity ratio of 0.56. OSI Systems has a 12 month low of $126.57 and a 12 month high of $220.00. Read Our Latest Research Report on OSISNVE (NVEC)NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.NVEC stock traded up $0.12 during trading hours on Friday, hitting $57.09. 27,121 shares of the stock were exchanged, compared to its average volume of 22,239. The company has a 50-day simple moving average of $65.46 and a two-hundred day simple moving average of $73.68. The firm has a market capitalization of $276.14 million, a P/E ratio of 18.42 and a beta of 1.05. NVE has a 12 month low of $51.50 and a 12 month high of $89.98. Read Our Latest Research Report on NVECBiodexa Pharmaceuticals (BDRX)Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.NASDAQ BDRX traded down $0.03 during trading on Friday, reaching $1.43. The company's stock had a trading volume of 83,028 shares, compared to its average volume of 592,474. Biodexa Pharmaceuticals has a 12 month low of $1.14 and a 12 month high of $74.00. The firm has a 50 day moving average price of $2.48 and a 200 day moving average price of $4.02. Read Our Latest Research Report on BDRXClene (CLNN)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.Shares of NASDAQ CLNN traded down $0.02 during mid-day trading on Friday, reaching $3.00. The company had a trading volume of 15,345 shares, compared to its average volume of 75,717. Clene has a one year low of $2.57 and a one year high of $9.20. The business's 50-day simple moving average is $3.88 and its 200 day simple moving average is $4.60. The firm has a market cap of $25.79 million, a price-to-earnings ratio of -0.57 and a beta of 0.46. Read Our Latest Research Report on CLNNVirpax Pharmaceuticals (VRPX)Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.Shares of NASDAQ:VRPX traded up $0.05 during midday trading on Friday, hitting $0.26. The stock had a trading volume of 18,174 shares, compared to its average volume of 200,011. The company's 50-day moving average price is $3.45 and its 200-day moving average price is $8.82. Virpax Pharmaceuticals has a fifty-two week low of $0.13 and a fifty-two week high of $101.00. Read Our Latest Research Report on VRPXFeatured StoriesMarketBeat's Top Five Stocks to Own in April 20253 Mid-Cap to Mega-Cap Stocks Have Announced Significant BuybacksThese 3 Stocks Have Huge Last 12 Months Shareholder YieldsProminent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?Strategic Reset Begins: Intel Sells Controlling Stake in AlteraTariff-Resistant Kinder Morgan Is a Good Buy in 2025This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in OSI Systems Right Now?Before you consider OSI Systems, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OSI Systems wasn't on the list.While OSI Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here